Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 16, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, authorized by shareholders at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 2,100,000 ordinary shares of 25 pence each.
- Purchase Price: 1,270.82 pence per share.
- Treasury Holdings: Following the purchase, GSK holds 444,689,158 shares in Treasury.
- Voting Rights Impact: Treasury shares represent 7.97% of total voting rights.
- Shares in Issue: 5,580,017,438 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares due to the repurchase of 2,100,000 shares on October 16, 2007. Consequently, the total number of shares held in Treasury increased to 444,689,158. The filing does not provide comparative data against prior periods for operational or financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies beyond the standard disclosure that the announcement does not constitute an offer to purchase securities. The transaction was executed in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total number of shares in issue (5,580,017,438) for accurate calculation of ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (444,689,158) and its impact on the 7.97% voting rights dilution.
- Note that this filing is a notification of a specific share repurchase event and does not contain quarterly or annual financial performance data.